Skip to main content

Advertisement

Table 2 Summary of Adverse Events in Patients With and Without Daily Headache

From: Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

AE, n (%) With Daily Headache (n = 138) Without Daily Headache (n = 504)
≥1 AE 99 (71.7) 297 (58.9)
Serious AE 20 (14.5) 44 (8.7)
Study discontinuation due to AE 10 (7.2) 17 (3.4)
≥1 TRAE 24 (17.4) 97 (19.2)
Individual TRAEs occurring in ≥1% of any subgroup
 Neck pain 5 (3.6) 23 (4.6)
 Eyelid ptosis 3 (2.2) 14 (2.8)
 Musculoskeletal stiffness 4 (2.9) 13 (2.6)
 Injection site pain 3 (2.2) 11 (2.2)
 Headache 2 (1.4) 8 (1.6)
 Muscular weakness 1 (0.7) 9 (1.8)
 Facial paresis 1 (0.7) 6 (1.2)
 Migraine 0 (0.0) 6 (1.2)
 Skin tightness 1 (0.7) 5 (1.0)
 Influenza-like illness 2 (1.4) 1 (0.2)
 Balance disorder 2 (1.4) 0 (0.0)
 Dizziness 3 (2.2) 0 (0.0)
  1. AE adverse event, TRAE treatment-related adverse event